22,473 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV bought a new stake in Boston Scientific Co. (NYSE:BSX) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 22,473 shares of the medical equipment provider’s stock, valued at approximately $2,267,000.

Several other large investors also recently bought and sold shares of BSX. Colonial Trust Co SC raised its position in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 260 shares during the last quarter. Investment Management Corp VA ADV acquired a new position in shares of Boston Scientific in the fourth quarter worth $25,000. Sunbeam Capital Management LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at $26,000. Ameriflex Group Inc. acquired a new stake in shares of Boston Scientific during the fourth quarter valued at $31,000. Finally, Fairway Wealth LLC acquired a new stake in shares of Boston Scientific during the fourth quarter valued at $36,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Robert W. Baird upped their target price on shares of Boston Scientific from $115.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, April 24th. Argus set a $130.00 price objective on shares of Boston Scientific in a research note on Tuesday, February 18th. Morgan Stanley boosted their price target on Boston Scientific from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, May 16th. Citigroup restated a “buy” rating and set a $125.00 price objective (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Finally, BTIG Research reiterated a “buy” rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, April 23rd. Twenty-one research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $116.00.

Insider Transactions at Boston Scientific

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the sale, the senior vice president now directly owns 36,193 shares in the company, valued at $3,441,592.37. The trade was a 11.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $102.48, for a total value of $16,852,118.64. Following the transaction, the chief executive officer now owns 1,535,706 shares of the company’s stock, valued at approximately $157,379,150.88. This trade represents a 9.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 411,970 shares of company stock valued at $42,406,693. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Up 1.1%

BSX opened at $99.60 on Friday. The firm’s 50 day moving average is $101.03 and its 200-day moving average is $98.74. Boston Scientific Co. has a 52-week low of $71.88 and a 52-week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $147.35 billion, a P/E ratio of 79.68, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the previous year, the firm posted $0.56 EPS. The firm’s quarterly revenue was up 20.9% on a year-over-year basis. Analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.